Dashboard
1
High Debt company with Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 6.35% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
With ROE of 7.31%, it has a Very Expensive valuation with a 0.99 Price to Book Value
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
EUR 5,137 Million (Mid Cap)
14.00
NA
2.49%
1.47
7.31%
0.99
Revenue and Profits:
Net Sales:
1,891 Million
(Quarterly Results - Jun 2025)
Net Profit:
138 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.46%
0%
-10.46%
6 Months
2.42%
0%
2.42%
1 Year
12.63%
0%
12.63%
2 Years
-22.49%
0%
-22.49%
3 Years
7.58%
0%
7.58%
4 Years
-29.98%
0%
-29.98%
5 Years
-55.25%
0%
-55.25%
Grifols SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.44%
EBIT Growth (5y)
6.35%
EBIT to Interest (avg)
3.05
Debt to EBITDA (avg)
4.51
Net Debt to Equity (avg)
1.65
Sales to Capital Employed (avg)
0.41
Tax Ratio
47.48%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
9.46%
ROE (avg)
10.00%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
0.99
EV to EBIT
9.47
EV to EBITDA
7.16
EV to Capital Employed
1.00
EV to Sales
1.69
PEG Ratio
0.19
Dividend Yield
2.49%
ROCE (Latest)
10.53%
ROE (Latest)
7.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
1,891.10
1,817.90
4.03%
Operating Profit (PBDIT) excl Other Income
446.50
364.50
22.50%
Interest
159.30
221.40
-28.05%
Exceptional Items
25.90
-1.50
1,826.67%
Consolidate Net Profit
138.40
24.80
458.06%
Operating Profit Margin (Excl OI)
184.80%
138.80%
4.60%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 4.03% vs 9.28% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 458.06% vs -72.41% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
7,212.40
6,592.00
9.41%
Operating Profit (PBDIT) excl Other Income
1,562.30
1,137.00
37.41%
Interest
714.80
596.90
19.75%
Exceptional Items
10.80
1.50
620.00%
Consolidate Net Profit
212.80
163.70
29.99%
Operating Profit Margin (Excl OI)
155.90%
104.80%
5.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 9.41% vs 8.71% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 29.99% vs -39.62% in Dec 2023
About Grifols SA 
Grifols SA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






